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Recent immunotherapy treatments are
showing promising results in cancer
management, but a proportion of pa-
tients do not fully benefit from therapy
and fail to achieve durable responses or
experience relapse.
Chimeric antigen receptor (CAR) vector
insertion at epigenetic chromosomal
sites may determine the potency and
durability of CAR-T cell cytotoxic re-
sponses, as shown for the complete
remission of a chronic lymphocytic leuke-
mia (CLL) patient with TET2 disruptionEffective anticancer immunotherapy treatments constitute a qualitative leap in
cancer management. Nonetheless, not all patients benefit from such therapies
because they fail to achieve complete responses, suffer frequent relapses, or
develop potentially life-threatening toxicities. Epigenomic signatures in immune
and cancer cells appear to be accurate and promising predictors of patient out-
comes with immunotherapy. In addition, combined treatments with epigenetic
drugs can exploit the dynamic nature of epigenetic changes to potentially modu-
late responses to immunotherapy. Candidate epigenetic biomarkers may provide
a rationale for patient stratification and precision medicine, thus maximizing the
chances of treatment success while minimizing unwanted effects. We present
a comprehensive up-to-date view of potential epigenetic biomarkers in immuno-
therapy and discuss their advantages over other indicators.caused by CAR19 vector integration.
Novel biomarkers of response are
needed, and epigenetic biomarkers
may represent solid candidates for filling
this niche, thereby contributing to
theragnosis and precision medicine.
Combinatorial approaches of epige-
netic drugs with immunotherapy may
synergize to reshape the tumor micro-
environment and restore an effective
antitumor response, thus overcoming
immunotherapy limitations for some
cancer types.
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(M. Esteller).Predicting Immunotherapy Success or Failure: The Importance of Developing
Reliable ‘Biomarkers’
Immunotherapy (see Glossary) has become a game changer in cancer treatment. It relies on
enhancing the patient’s immune defenses to combat tumor cells. However, the significant
proportion of nonresponding cases and treatment-associated toxicities remain an obstacle to
therapeutic success. Therefore, it is important to discover and develop good predictors of
therapy efficacy and/or toxicity such that treatments can be personalized and the chances of a
cure increased. We discuss in depth the latest research on epigenetic marks as biomarkers for
immunotherapy, their potential and limitations, and the preclinical and clinical studies currently
being conducted; we provide comprehensive and novel insights into their present and future
usage in the clinic.
Cutting-Edge Immunotherapy-Based Strategies and Their Limitations
Immunomodulatory agents targeting the interferon (IFN)-α2b pathway or the interleukin (IL)-2/IL-2R
axis (aldesleukin) were approved by the US FDA in 1986 and 1992 for the treatment of leukemia
and melanoma, respectively. Subsequently, the monoclonal antibody (Ab) rituximab, which targets
B cell CD20, was approved by the FDA for non-Hodgkin lymphoma. Since then, Ab-based thera-
pies have substantially improved with the development of bispecific and trispecific antibodies
[1] that may allow more precise and effective treatment strategies. Therapeutic vaccination against
cancer also emerged as a promising immunotherapeutic strategy at the beginning of the 21st
century, leading to FDA approval of the dendritic cell (DC)-based vaccine sipuleucel_T for the treat-
ment of prostate cancer in 2010. In this context, the arrival of immune checkpoint blockade
(ICB) therapy was a tipping point that created new possibilities for clinical applications.
Since FDA approval in 2011 of the cytotoxic T-lymphocyte antigen 4 (CTLA-4) targeting ICB
ipilimumab to treat metastatic melanoma,many immunotherapeutic approaches targeting immune
checkpoint molecules have been included in clinical practice guidelines for cancer treatments.
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Glossary
Apoptosis: a highly regulated
programmed cell death mechanism that
occurs in the absence of cell membrane
breakage, ensuring the correct disposal
of dysfunctional cells.
Bispecific and trispecific antibodies:
genetically engineered monoclonal
immunoglobulins that respectively target




side-effect developed in some patients
following CAR-T cell infusion.
Chimeric antigen receptor (CAR)
T cell therapy: an immunotherapy
approach in which T cells are genetically
engineered in the laboratory to recognize
targeted antigens expressed in tumor
cells.
CpG islands: genomic regions enriched
in cytosine and guanine dinucleotides;
CpG islands are located in DNA
regulatory regions such as promoters.
Cytokine-release syndrome (CRS):
a systemic inflammatory response that is
triggered, for example, by CAR-T cell
activation following targeted antigen
recognition.
Deconvolution analysis: a
computational method to infer the
proportion of components and their
relative contributions to a particular
signal from a complex sample.
Epigenetic biomarker: a modification
or signature used as a qualitative and/or
quantitative putative indicator of
physiological/pathological conditions, or
in response to treatment.
Epigenetic drug: targets epigenome-
related pathological changes to allow the
treatment of several disorders, including
cancer.
Epigenetic fingerprints: molecular
signatures comprising sets of epigenetic
modifications relative to a particular
condition.
Exhaustion: a state of cell dysfunction
accompanied by progressive loss of
effector function that occurs after
persistent antigen stimulation.
Immune checkpoint blockade (ICB):
an immunotherapy that abolishes
inhibitory signals in tumor-associated
immune cells, thus supporting an
effective anticancer T cell response.
Immunological synapse: contact
between an antigen-presenting or target
cell and a lymphoid lineage cell that
orchestrates lymphocyte activation and
a subsequent immune response.
Trends in Immunologywere approved by the FDA in 2014 and 2015, respectively, for the treatment of various solid and
hematological malignancies. PD-L1 blockers atezolizumab and avelumab were FDA-approved in
2017 and durvalumab in 2018 for the treatment of bladder, lung, and Merkell cell carcinoma.
One of the latest FDA-approved ICB molecules is the anti-PD-1 monoclonal Ab cemiplimab for
metastatic cutaneous squamous cell carcinoma. Other promising immune receptors such as
LAG-3, TIM-3, TIGIT, VISTA, OX40, CD40, 4-1BB, and GITR are currently under investigation in
preclinical studies [2].
The success of immunotherapy success has extended to adoptive cell therapieswith the approval of
chimeric antigen receptor (CAR) T cell therapy by the FDA, followed by other promising
strategies such as tumor-infiltrating lymphocytes (TILs) and T cell receptor (TCR)-
engineered cells that are currently being tested in various advanced clinical trials for different
malignancies (clinicaltrials.gov). Novel CAR-based strategies using natural killer cells (CAR-NK) in
conjunction with lymphodepleting chemotherapy are also showing encouraging results in a single-
arm dose-escalation Phase I/IIa trial (NCT03056339i, recruiting) in which 73% of patients with
non-Hodgkin's lymphoma or chronic lymphocytic leukemia (CLL) responded to treatment [3].
Nonetheless, beyond tumor intrinsic resistance to ICB, there are innate and adaptive mecha-
nisms that affect antitumor-specific T cell activation, expansion, and exhaustion [2,4], leading to
response failure. In addition, treatment can be associated with potentially life-threatening
autoimmune-like toxicities leading to specific organ damage [5]. In general, the incidence
of immune-related adverse effects (irAEs) is higher with combined therapies than with anti-
PD-1/anti-PD-L1 Ab (66%) or anti-CTLA-4 Ab monotherapies (72%) [5]. In addition, combined
blockade showed a higher fatality rate (1.23%) than anti-PD-1/anti-PD-L1 Abs (0.37%) and
CTLA-4 blockers (1.08%) administered separately, according to a meta-analysis conducted in
19 217 ICB-treated patients with 25 types of solid cancers, mainly melanoma and lung cancer
[6]. Severe-grade toxicities are mostly associated with anti-CTLA-4 therapies, where colitis is the
primary cause of irAES-related death, affecting 8–22% of patients with melanoma treated with
anti-CTLA-4 Ab [7]. Pulmonary toxicity (5%with anti-PD-1/anti-PD-L1 Abs, or combined treatment
with anti-CTLA-4 Ab) and hepatitis incidence (3–9%with anti-CTLA-4 Abs) are low, but with poten-
tially fatal consequences, mainly in melanoma and lung cancer [5]. A meta-analysis of 38 clinical
trials carried out in different solid cancers showed that endocrine affectations such as pituitary
or thyroid toxicity can appear after CTLA-4 or combined therapy, leading to gonad dysfunction
[5]. In the case of CAR-T cell therapy, severe adverse toxicities, including cytokine-release
syndrome [8], and CAR-T cell-related encephalopathy syndrome (CRES) [9], are more
frequent. Thus, beyond most clinical indications and guidelines, it is essential to develop new
biomarkers that will enable us not only to predict the intensity and duration of a clinical
response (if any) but also the risk of developing important adverse effects, and thereby rationalize
the use of these expensive customized therapeutic strategies.
Epigenetic Biomarkers: Pros and Cons
Molecules that act as predictors of the cancer response to immunotherapy (termed biomarkers)
are commonly used in personalized cancer immunotherapy: these include PD-L1 expression
[10], tumor-associated antigens (TAAs) [11], HLA expression [12], TCR repertoire assessments
[13], tumor mutational burden and neoantigen identification [14],mismatch repair deficiency
[15], the presence of TILs [16], and the presence of cells within the tumor microenvironment
(TME) that might potentially inhibit antitumor immune responses [e.g., regulatory T cells
(Tregs), tumor-associated macrophages (TAMs), and/or polymorphonuclear myeloid-
derived suppressor cells (PMN-MDSCs)] [4,17], as well as the incidence of genetic alterations
[18] that are associated with treatment response. The epigenetic control of these events has beenTrends in Immunology, August 2020, Vol. 41, No. 8 677
Immunotherapy: a therapeutic
intervention aiming to enhance the
patient's own immune system.
Lineage switch: a conversion
phenomenon affecting hematopoietic
lineages: one cell lineage transforms into
a different lineage that exhibits distinct
lineage-defining markers.
Mismatch repair deficiency: a cellular
defect in mismatch repair (i.e., genetic
mutations in the machinery that corrects
mistakes due to DNA replication),
resulting in the accumulation of
mutations by the cell.
Polymorphonuclear myeloid-
derived suppressor cells
(PMN-MDSCs): immune cells involved
in an immunosuppressive response.
Proto-oncogenes: genes that regulate
Trends in Immunologyextensively demonstrated, supporting the relevance of using specific epigenetic changes (Box 1)
as potential biomarkers for immunotherapy. Cancer cell-intrinsic epigenetic alterations have been
associated with carcinogenesis [19,20], tumor progression [21,22], and treatment resistance as
a result of lineage switch in B cell lymphoma and leukemia [23]. Finally, treatment itself may
cause epigenetic alterations, as evidenced from DNA methylation of relevant genes including
CD96, HHLA2, CCR5, CXCR5, and CCL5 in CD8+ T cells purified from healthy donors following
immunotherapy [24] (see Outstanding Questions).
Epigenetic biomarkers may offer additional advantages, such as low patient invasiveness,
given that changes in DNA methylation can be measured in liquid biopsies and body fluids [25].
They can also convey a layer of information about the life habits and conditions of patients, and
reveal details about the origin and evolution of a given disease [26]. In some instances, as
discussed later for lung cancer [27], they can serve as diagnostic, prognostic, predictive, and
therapy-monitoring indicators, facilitating the fostering of theragnosis and precision medicine
[26]. Despite the great potential of epigenetic modifications as putative biomarkers, some caveatscell proliferation and differentiation; can
potentially drive cancer whenmutated or
aberrantly expressed.
Regulatory T cells (Tregs): a
subpopulation of CD4+ T cells that
dampen the immune response,
preventing autoimmune diseases or
promoting tumor progression by
suppressing antitumor responses.
T cell receptor (TCR)-engineered
cells: cells encoding an engineered
TCR that has been inserted as part of an
immunotherapeutic strategy.
TCR repertoire: TCR antigen-specific
diversity produced by V(D)J gene
rearrangement during T cell development.
Th1 cytokines: produced by CD4+
helper T cells associated with
proinflammatory responses.
Transcriptional regulation: control
mechanisms of RNA transcription in
response to various signals that
coordinate gene expression.
Tumor-associated macrophages
(TAMs): myeloid cells associated with
the TME that modulate the antitumor
response.
Tumor escape: evasion of the immune




(TILs): immune cells that migrate into
the tumor and can potentially recognize
and eliminate cancer cells.
Tumor intrinsic resistance:
nonresponsiveness to therapy owing to
failure of the immune system to elicit an
effective antitumor immune response.
Tumormicroenvironment (TME): the
surroundings of a tumor composed of
resident and recruited immune cells,
fibroblasts, secreted soluble molecules,
Box 1. Epigenetic Modifications: DNA Methylation, Histone Modifications, and Noncoding RNAs
The term epigenetics comprises mitotically heritable changes that affect gene expression without modifying the primary
genome DNA sequence. Epigenetic modifications include DNA methylation, modification of histone tails, and noncoding
(nc) RNAs. Epigenetic alterations are key in directing the aberrant expression of tumor-associated genes that drive cellular
malignant transformation and cancer progression.
DNA Methylation
The most abundant mark on DNA occurs via addition of a methyl (CH3) group by DNA methyltransferases (DNMTs) at the 5′
position on the pyrimidine ring of cytosine residues in the context of a CpG dinucleotide. DNA methylation affects transcrip-
tion factor binding and controls accessibility to regulatory regions in the DNA, modulating gene expression [85]. Aberrant
modifications of 5-methylcytosine (5mC) profiles can promote uncontrolled cell proliferation and survival, as well as
supporting tumor growth. Silencing of tumor-suppressor genes through promoter hypermethylation is a hallmark of many
cancer types [86]. Removal of 5mCs occurs by sequential oxidation by TET enzymes (in dividing mammalian cells),
generating 5-hydroxymethylcytosine (5hmC), 5-carboxycytosine (5caC), 5-formylcytosine (5fmC), and unmethylated C.
Accumulating evidence suggests that oxidized intermediate forms could represent bona fide epigenetic marks [87,88].
Post-translational Histone Modifications
These control gene expression by modulating chromatin conformation and accessibility. Families of histone-modifying
enzymes target specific residues at histone tails in response to external signals. The most frequent histone modifications
include acetylation, methylation, and phosphorylation, but others including citrullination, ubiquitination, ADP-ribosylation,
deamination, formylation, O-GlcNAcylation, propionylation, butyrylation, crotonylation, proline isomerization, and the
recently discovered lactylation have also been described [89].
Acetylation. This mark consists of the reversible addition of an acetyl group (-CH3CO) to lysine residues and is associated
with gene transcription activation. Histone acetyltransferases (HATs) are chromatin writers that add acetyl groups,
whereas histone deacetylases (HDACs) are erasers that remove this mark.
Methylation. The addition of methyl groups (-CH3) to lysine and/or arginine residues in histone tails is catalyzed by several
histone methyl transferases (HMTs), whereas histone demethylases (HDMs) catalyze removal. Depending on the specific
modified residue, methylation marks can be categorized as activating (e.g., H3K4me3) or repressive (H3K9me3,
H3K27me3).
Phosphorylation.Histone phosphorylation occursmainly at serine (S), threonine (T), and tyrosine (Y) residues of histone tails and
is positively associated with transcription and an accessible chromatin conformation. Histone H3 phosphorylation at tyrosine
41 (H3Y41) is enriched at active promoters close to transcription start-sites (TSS) together with the H3K4me3 mark.
ncRNAs
ncRNAs represent ~90% of human genome-derived RNAs, and include several different types of ncRNA that are classified
according to size. ncRNAs N200 bp in length include long ncRNAs (lncRNAs), pseudogene transcripts, and circular RNAs
(circRNAs). miRNAs, tRNA-derived small RNAs (tsRNAs), and PIWI-interacting RNAs (piRNAs) are ncRNAs b200 bp in
length. Dysregulation of ncRNA expression contributes to the pathogenesis of many diseases including cancer [90].
678 Trends in Immunology, August 2020, Vol. 41, No. 8blood vessels, and extracellular matrix.
Tumor mutational burden: the total
number of nonsynonymous somatic
mutations accumulated by the tumor cell
genome.
Whole-genome bisulfate
sequencing (WGBS): a next-
generation sequencing technique;
consists of deep sequencing an entire
genome after sodium bisulfite
modification to analyze DNA
methylation.
Trends in Immunologyand specific requirements need to be addressed. Candidate epigenetic biomarkers must
be tested in homogeneous and reliable patient cohorts (clinical trials). In addition, sensitive
and precise detection methods need to be developed to facilitate the discovery of new
epigenetic fingerprints (see Outstanding Questions). Finally, clinical laboratories must be
adapted for marker analysis, which should accompany other prognostic and diagnostic
approaches (Box 2).
Epigenetic Modifications That Modulate Antitumor Immunity: Can They Help To
Predict Immunotherapy Success?
The sum of accumulated genetic mutations and aberrant changes in the chromatin landscape
disrupts cellular homeostasis, and this can lead to cancer initiation and promote tumor progres-
sion. Genetic and epigenetic mechanisms cooperate intricately and can act as cancer drivers.
Frequent mutations in cancer include those leading to aberrant expression and/or activity of
chromatin-modifying enzymes [26].Box 2. Laboratory Methods for Analyzing Epigenetic Modifications
Methods for studying epigenetic changes can interrogate a single locus or cover the whole genome.
DNA Methylation
Methylation can be analyzed by methods that include:
(i) Bisulfite conversion of DNA. Genomic DNA is treated with sodium bisulfite, which changes unmethylated cytosines to
uracil, whereas 5mC is unchanged. The identification and quantification of modified compared with unmodified cyto-
sines at single loci can be assessed by pyrosequencing. By contrast, DNA methylation arrays and whole-genome
bisulfite sequencing (WGBS) – based on high-throughput next-generation sequencing (NGS) – allow genome-wide
(with single-base resolution) or whole-genome interrogation, respectively.
(ii) Enzymatic digestion of DNA. This is based on the recognition and fragmentation of genomic DNA by methylation-
sensitive restriction enzymes such as MspI, and subsequent analysis of the fragments by NGS.
(iii) Reduced representation bisulfite sequencing (RRBS). Combines enzymatic digestion and bisulfite conversion to
generate fragments enriched in CpG-rich regulatory regions, such as promoters, that are then analyzed by parallel
sequencing, reducing costs compared with sequencing of the entire genome.
(iv) Affinity-based methods (such as methylated DNA immunoprecipitation sequencing, MeDIP). These are based on
enrichment of selected DNA fragments by pulling down genomic DNA with either antibodies or DNA-binding proteins.
The enriched fraction is then analyzed by sequencing. One advantage of affinity-based methods is that they allow
interrogation of relevant DNA methylation variants such as 5hmC, as in the 5hMeDIP protocol.
Post-translational Histone Modifications
These are mainly assessed by immunoprecipitation with specific antibodies (e.g., against histone modifications or histone
variants) to pull down protein–DNA complexes. The DNA is then analyzed by PCR, arrays, or massively parallel sequencing
(ChIP-PCR, ChIP-on-ChIP, or ChIP-seq, respectively).
Chromatin Structure and Accessibility
Analysis of these key epigenetic features is informative regarding the molecular mechanisms of pathogenicity. Methods to
study accessibility and nucleosome positioning are based on enzymatic digestion and isolation of either nucleosome-
bound or accessible regions of DNA coupled to NGS.
Micrococcal Nuclease (MNase)-Seq
Allows interrogation of nucleosome-protected DNA by digesting nucleosome-free genomic regions with MNase from
Staphylococcus aureus. Undigested DNA represents DNA bound to nucleosomes, which is recovered and sequenced.
Assay for Transposase-Accessible Chromatin (ATAC)-Seq
This method assesses the accessibility of chromatin; it is based on the cutting and addition of adapters to the genomic
DNA by Tn5 transposase. In this process, called tagmentation, DNA is amplified by PCR and analyzed by NGS. An
open chromatin conformation correlates with the frequency of sequences that map to a given genomic region. Recently,
heterogeneity in samples can also be assessed by single-cell ATAC-Seq (scATAC-Seq) protocols that rely on a first step of
single-cell separation before ATAC library preparation and sequencing.
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The genetic component of tumorigenesis includes mutations that cause activation of oncogenic
genes or inactivation of tumor-suppressor genes. However, at the epigenetic level, transcriptional
regulation of tumor-associated genes can drive oncogenesis. Cancerous cells often feature
increased transcription of proto-oncogenes as a result of promoter hyperacetylation [28,29],
concomitant with repression of tumor-suppressor genes by promoter hypoacetylation and
DNA hypermethylation [30]. Many cancer types show a global loss of DNA methylation through-
out the genome, with gains of DNA methylation specifically located at CpG islands, thus
repressing genes that control cancer growth, such as tumor-suppressor genes [31,32]. Recently,
changes in oxidized intermediate 5hmC (5-hydroxymethylcytosine) profiles have been associated
with tumor aggressiveness and a less-differentiated phenotype, both in KRAS mutant mouse
models of pancreatic ductal adenocarcinoma (including Pdx1-cre;LSL-KrasG12D;Col1a1-TRE-
shp53-shRenilla;Rosa26-CAGs-LSL-rtTA-IRES-mKate2) [33] and in some human hematological
malignancies such as acute myeloid leukemia (AML) [34].
Accompanying extensivemodification of the tumor cell epigenome, reconfiguration of the TME and
tumor-driven rewiring of immune cell chromatin landscapes can also modulate the extent and
quality of the antitumor immune response, the potential response to immunotherapy, and overall
disease outcome. A protumorigenic immunosuppressive TME epigenetically affects immune
cells, and can lead to tumor escape [28,35]. From the extent of cellular accumulation of TILs in
the TME, tumors may be arbitrarily classified as 'hot', when highly or modestly infiltrated, or
'cold', if they are noninfiltrated tumors [36]. Inflamed 'hot' TMEs are compatible with effective
type 1 T helper (Th1) cell IFN-γ-mediated antitumor immune responses, as shown by the correla-
tion between the presence of an IFN-responsive genes signature in some tumors (e.g., melanoma,
and head and neck squamous cell carcinoma, HNSCC), and a better response to immunotherapy,
compared with tumors lacking the IFN-γ signature [37]. For the above reasons, it is crucial to
understand how tumors shape an immunosuppressive TME. TILs, particularly cytotoxic CD8+
T cells (CTLs), often display an ‘exhausted’ phenotype resulting from persistent antigen stimulation
[38,39]; an immunosuppressive TME can contribute to tumor-specific CTL exhaustion, as shown
in a mouse model of tamoxifen-inducible liver cancer (ASTxCre-ERT2) [38]. CD8+ T cell exhaustion
features specific chromatin-accessible regions associated with an altered transcriptional profile,
including enrichment for genes such as Pdcd1 (encoding PD-1), and the Ifng and Il10 signaling
pathways [40]. Finally, concomitant extensive epigenetic reprogramming [41] leading to silencing
of genes involved in effector differentiation, such as Ifng, Tcf7, Myc, and Ccr7, have resulted in
loss of CD8+ T cell effector function in mice [42,43] (Figure 1). Of relevance, anti-PD-1 Ab therapy
can partially reverse CD8+ T cell exhaustion, but achieving a durable antitumor CD8+ T cell effector
response has proved challenging [44]. Chromatin states can differentiate dysfunctional tumor-
infiltrated PD-1-positive CD8+ T cells, whose exhaustion might be reversed, from those that are
potentially refractory to anti-PD-1 Ab therapeutic intervention [45]. Tumor antigen-specific CD8+
T cells are rendered dysfunctional during tumorigenesis in a tamoxifen-inducible hepatocellular
carcinomamurinemodel (ASTxCre-ERT2), and they fail to produce IFN-γ and tumor necrosis factor
(TNF)-α as a result of chromatin remodeling, as evidenced from ATAC (assay for transposase-
accessible chromatin)-seq data [45]. Such epigenetic reconfiguration can be reverted by ex vivo
treatment with IL-15 [45]. Similar chromatin-accessibility profiles have been described in human
TILs from melanoma and non-small cell lung tumors (NSCLC) [45]. From another angle, double-
stranded RNAs (dsRNAs) can accumulate in cancer cells upon derepression of endogenous retro-
viruses (ERVs) by epigenetic drugs such as DNA demethylating agents and lysine demethylase 1
(LSD1) inhibitors in ovarian cancer cell lines [46]. This is relevant because cytoplasmic accumulation
of dsRNAs mimics viral infection, triggering an IFN response within the TME and promoting robust
antitumoral immunity [46]. In cell lines derived from hematological cancers and ovarian cancer, dual680 Trends in Immunology, August 2020, Vol. 41, No. 8
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Figure 1. Intrinsic Mechanisms Driving CD8+ T Cell Exhaustion in Cancer. In addition to immunosuppressive factors
in the tumor microenvironment (TME), transcriptional regulation and epigenetic restraining through DNA methylation and
repressive histone marks can induce a dysfunctional CD8+ T cell state. (A) An increase in transcription factors such as TOX,
NRA4, EOMES, and NFAT, that upregulate the expression of inhibitory receptor genes, including Pdcd1, Havcr2, and Lag3
(which encode PD-1, TIM3, and LAG3) among others, is associated with a terminally ‘exhausted’ phenotype [40,42,100].
(B) EZH2, part of the PRC2 H3K27me3 chromatin writer complex, is a key regulator of transcriptional silencing of memory-
associated genes that leads to terminally differentiated effector CD8+ T cells [41]. This repressive mark has been associated
with tumor-specific CTL dysfunction in pre- and early malignant lesions [38]. DNA methylation enzymes, such as DNMT1
and DNMT3B, are upregulated in exhausted CD8+ T cells [38] and DNMT3A genome-wide de novo methylation can
promote terminal exhaustion [43]. Black arrows represent an upregulation of epigenetic enzymes recruitment and red
crosses represent transcriptional repression. This figure was created using BioRender (https://biorender.com/).
Abbreviations: CTL, cytotoxic T lymphocyte; DNMT, DNAmethyltransferase; H3K27me3, histoneH3 trimethylated on lysine 27.
Trends in Immunologyinhibition of methyltransferase G9a and DNA methyltransferases (DNMTs) caused upregulation of
nonoverlapping groups of ERV transcripts, with subsequent induction of viral defense genes such
as those encoding IRF7 and STAT1 [46,47]. In colorectal cancer initiating cell lines (CICs), treatment
with the demethylating agent 5-AZA (5-aza-2-deoxycytidine) induces IFN response factors such as
IRF7 and OASL by prompting dsRNA upregulation and activating the MDA5/MAVS/IRF7 signaling
pathway [48]. Thus, targeting of cancer cells with epigenetic drugs can induce viral mimicry leading
to activation of IFN responses that promote effective immune responses; these, if combined with
checkpoint inhibition therapy, might potentially enhance antitumoral responses and increase
therapeutic success.
Epigenetic Modifications as Putative Biomarkers for Immunotherapy
Several preclinical studies in mice, cell lines, and patient samples propose potential epigenetic
biomarkers whose fingerprints are associated with immune evasion or response signatures
that can be used as indicators of immunotherapy efficacy (Table 1 and Outstanding
Questions). Of note, most studies to date describe biomarkers in bulk tissue preparations, and
further information regarding biomarkers at the cellular level is still missing.Deconvolution anal-
ysis of transcriptomic and epigenomic data from tumor tissues is a potent tool for identifying the
cell types that express dysregulated genes [49]. Indeed, DNA methylation-based deconvolutionTrends in Immunology, August 2020, Vol. 41, No. 8 681
Table 1. Potential Epigenetic Biomarkers Corresponding to an Immunocompetent Phenotype
Putative biomarker Mark Source Malignancy Refs
CD8+ T cell infiltration H3K27me3 at Th-1 genes Mouse Ovarian cancer [35]
Lysine demethylase 1 (LSD1)
inhibition
Mouse Melanoma [51]



















CD8+ T cell exhaustion PRF1 methylation Human (ex vivo) Urothelial bladder cancer
(UBC)
[63]





H3K27me3 H3K27ac Human Gastric adenocarcinoma [64]






Small cell lung cancer
(SCLC)
[58]
HLA, CD40, CD80, CD86
methylation
TCGA Pan-cancer [56]
Novel ICB treatments ADORA2A methylation TCGA HNSCC [61]
TNFRSF9 methylation Human Melanoma [62]
Trends in Immunologyanalysis revealed that aberrant activation of the transforming growth factor (TGF)-β pathway in
cancer-associated fibroblasts could drive immunosuppression in tumors that were originally
'hot', thus preventing a successful response to ICB [50]. Epigenetic silencing by EZH2-
mediated histone methylation and DNMT1 DNA methylation can constitute tumorigenic mecha-
nisms. In whole-tissue studies, inhibition of the epigenetic modifiers EZH2 and DNMT1 in tumor
cells from an ovarian cancer ID8 model in mice increased the expression of Th1 chemokine
genes Cxcl9 and Cxcl10 by the tumor [35]. Combined epigenetic treatment and immunotherapy
promoted increased CD8+ T cell infiltration and improved the anti-PD-L1 Ab therapeutic effect
compared with immunotherapy in the absence of EZH2 and DNMT1 inhibition [35]. Thus, epige-
netic modulation may revert the immune evasion caused by epigenetic silencing of Th1
chemokines [35]. Moreover, histone demethylase LSD1 genetic ablation in mouse syngeneic
melanoma tumor cells promoted CD4+ and CD8+ T cell tumor infiltration and increased tumor
cell immunogenicity in mice bearing LSD1-deficient B16 tumors, relative to their wild-type (WT)
counterparts [51]. Furthermore, leukemia inhibitory factor (LIF)-mediated epigenetic silencing of
Cxcl9 in TAMs isolated from an ID8 ovarian cancer mouse model correlated with reduced
CD8+ T cell tumor infiltration and limited anti-PD-1 Ab efficacy upon LIF blockade [52]. In
human ovarian cancer, CCL5 and CXCL9 overexpression leads to CD8+ T cell tumor infiltration
and longer patient survival and response to anti-PD-1 Ab ICB compared with nonoverexpressing
cells [53]. In addition, epigenetic silencing of Ccl5 by DNA methylation in ID8 mouse ovarian
cancer tissue led to impaired TIL recruitment and CXCL9 secretion by TAMs, as evidenced
from immunostaining and multispectral microscopy in Cxcl9-expressing tumors compared with
Cxcl9low tumors, yielding 'cold' tumors that decrease animal survival and the response to anti-682 Trends in Immunology, August 2020, Vol. 41, No. 8
Trends in ImmunologyPD-1 Ab [53]. In addition, The Cancer Genome Atlas (TCGA) identified a subtype of HNSCC,
characterized by inactivation of histone methyltransferase nuclear receptor-binding SET domain
protein 1 (NSD1), as well as by DNA hypomethylation, showing a 'cold' tumor phenotype with low
immune cell infiltration as well as low PD-1 expression in CD8+ T cells, relative to active NSD1-
expressing tumors [54]. The authors also demonstrated in a HNSCC xenograft mouse model
that Nsd1 knockdown in tumor cells resulted in downregulation of chemoattractant cytokines
and tumor immune desertification relative to control transduced WT tumors [54]. Hence, epige-
netic mechanisms that promote tumor recruitment of lymphocytes might synergize with subse-
quent ICB immunotherapy. The epigenetic status of PDCD1LG2 (encoding PD-L2) in cancer
cells also appears to be relevant, at least in some tumor types; specifically, methylation of several
CpGs within this locus have been associated not only with CD8+ T cell tumor infiltration but also
with a high tumor mutational burden in patients with gastric adenocarcinomas [55]. From another
perspective, analysis of TGCA DNA methylation data from 20 human solid tumors revealed that
hypomethylation of immunological synapse genes such as HLA, CD40, andCD80 in immuno-
genic tumors such as melanoma correlated with effector CD4+ and CD8+ T cell infiltrates modu-
lating the tolerogenicity of the TME [56]. Three different murine models of melanoma (B16-F10,
RIM3, and NrasQ61KInk4a−/−) have demonstrated upregulation of Ezh2 expression on tumors
upon anti-CTLA-4 Ab treatment [57]. Such upregulation results in the epigenetic repression of
tumor immunogenic genes, such as MHC-I genes and Cxcl9, reducing antigen processing and
presentation to immune cells relative to controls [57]. Accordingly, whole-genome CRISPR/
Cas9 screening in the erythroleukemia cell line K562 showed a repressive role of PRC2 on
MHC-I genes in tumor cells, leading to tumor growth and resistance to CTL-mediated tumor
cell killing in a murine model of small-cell lung cancer (SCLC). Moreover, EZH2 inhibition allowed
restoration of HLA gene expression [58]. In another study, ATAC-seq on sorted IFN-γ-treated
melanoma cells revealed an increase of open chromatin regions relative to untreated cells, leading
to higher STAT-1 occupancy on loci such asMHC-II and CD274, and driving transcriptomic fea-
tures of resistance to anti-CTLA-4 Ab treatment [59]. Indeed, the search for novel, robust, and
valid ICB targets is an active field of research. Molecules with immunomodulatory effects, such
as Adora 2A and galectin 3, can be epigenetically controlled in some cancers including prostate
and HNSCC, respectively [60], and are being proposed as potential biomarkers for patient strat-
ification. Specifically, low promoter ADORA2A DNA methylation in tumors from HNSCC patients
correlated with immune cell infiltration and overall survival (OS) [61]. Within the immune compart-
ment, CD8+ T cells show epigenetic signatures that might help to determine their antitumoral
potential upon ICB therapy. For instance, the T cell co-stimulatory receptor TNFRSF9 (also
known as 4-1BB/CD137), whose expression is regulated by DNA methylation, may be a
promising therapeutic target for melanoma treatment [62]. A recent study in a TCGA cohort of
cutaneous melanoma showed that DNA methylation status of the human TNFRSF9 promoter
correlated with the extent of lymphocyte (including NK cell) and macrophage infiltration into the
tumor [62]. Owing to the regulatory role of DNA methylation on TNFRSF9 expression in tumor-
infiltrating immune cells, and given that TNFRSF9 promotes immune activation, these findings
suggest a layer of epigenetic regulation of TNFRSF9 expression that contributes to enhanced
lymphocyte recruitment and activation by tumors, thereby promoting antitumoral responses
[62]. Finally, increased expression and promoter hypomethylation of TNFRSF9 correlated signifi-
cantly with higher progression-free survival (PFS) and robust response to anti-PD-1 Ab therapy
in melanoma patients, supporting its possible suitability as a predictive biomarker of the response
to immunotherapy [62].
Analysis bywhole-genomebisulfate sequencing (WGBS) of isolated virus-specific CD8+ T cells
from amousemodel of chronic infectionwith lymphocytic choriomeningitis virus (LMCV) strain clone
13 revealed the acquisition of exhaustion-associated DNA-methylation programs through de novoTrends in Immunology, August 2020, Vol. 41, No. 8 683
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same differentially methylated regions were observed in tumor-infiltrating PD-1highTim3+CD8+ T
cells isolated from a TRAMP-C2 prostate tumor mouse model. Of relevance, combined PD-L1
blockade and treatment with DNA demethylating agents reverted the exhaustion program and in-
duced proliferation of tumor-infiltrating PD1+CD8+ T cells, thus reducing tumor growth in these
mice compared with PD-L1 monotherapy [43]. Recently developed single-cell technologies
allowing the interrogation of the heterogeneity of complex samples are shedding light on the contri-
butions of different cell types to cancer responses to immunotherapy. In one study, single-cell
transcriptomic analysis of CD8+ TILs revealed two cellular subsets, progenitor and terminally
exhausted, that differed in their chromatin accessibility and transcription of Slamf6 and Havcr2
(encoding Tim-3), and which largely determined the cytotoxic capacity of these cells in response
to PD-1 blockade in mice bearing B16-OVA tumors [40]. In another study, DNA methylation of
sorted exhausted CD8+ tumor tissue-resident memory T cells (Trms) from urinary bladder cancer
patients was interrogated. Tumor-infiltrating Trm cells showed that low DNA methylation in an
enhancer region of the PRF1 locus correlated with high expression of the perforin protein, and
allowed restoration of Trm antitumoral cytotoxic activity upon TCR ex vivo stimulation in the pres-
ence of IL-15 [63]. Furthermore, single-cell transcriptional profiling identified a population of dys-
functional PD-1highCD8+ T cells with reduced chromatin accessibility in TCF7 regions; these cells
were associated with exhaustion and a failed response to checkpoint blockade in nonresponder
melanoma patients relative to responders [42]. Such evidence may support the rationale for
using epigenetic ‘biomarkers’ and transcriptional programs to delineate therapeutic strategies
that might drive or complement anticancer treatments [42].
Epigenetic modifications relevant to the immunotherapy response have also been identified in
patients treated with immunotherapeutic agents (Table 2). Comparison of histone modification pro-
files [histone H3 trimethylated or monomethylated on lysine 4 (H3K4me3, H3K4me1) or
acetylated on lysine 27 (H3K27ac)] in promoters of human primary gastric tumors, gastric cancer
cell lines, and normal gastric tissue revealed altered chromatin profiles in somatic promoters that
led to dysfunctional antigen presentation and tumor depletion of immunogenic peptides, hence re-
ducing tumor antigenicity, strongly suggesting an epigenetically controlled mechanism of
immune evasion of immunotherapy [64]. Early studies showed that tumor PDCD1LG1 (coding for
PD-L1) promoter methylation was associated with anti-PD-1 Ab resistance in patients with NSCLC
refractory to treatment with EGFR tyrosine kinase inhibitors, and who were treated with nivolumab
(anti-PD-1 Ab) [65]. The value of unambiguously assessing epigenetic biomarkers to facilitate the pre-
diction of response to immunotherapywas first demonstrated inmatched pretreatment and post-ICB
samples in a cohort of melanoma patients. Specifically, lower CTLA4methylation in malignant mela-
noma tissue samples from a TGCA cohort was associatedwith a stronger response to anti-PD-1 andTable 2. Epigenetic Hallmarks Identified in a Cohort of Cancer Patients Treated with Immunotherapy
Epigenetic mark Malignancy Treatment Outcome Refs
PD-L1 methylation NSCLC Anti-PD-1 Ab Anti-PD-1 Ab resistance [65]
Low CTLA-4 methylation Melanoma Anti-PD-1 Ab
Anti-CTLA-4 Ab
Response to therapy and overall survival [66]
H3K27ac/H3K4me3 Gastric cancer Anti-PD-1 Ab Resistance to anti-PD-1 Ab [70]






NSCLC Anti-PD-1 Ab Clinical benefit with PD-1 blockade [27]
Global low methylation Lung cancer Anti-PD-1 Ab Poor prognosis and lower tumor immunity [67]
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Trends in Immunologyanti-CTLA-4 Ab therapy and increased OS compared with the non-ICB cohort [66]. Subsequent
studies have highlighted the role of epigenetics in predicting or modulating the immune response to
immunotherapy. A multicenter study conducted in tumor tissue from NSCLC patients treated with
anti-PD-1 Ab compared the presence and absence of an epigenetic signature (named EPIMMUNE),
and showed that the presence of EPIMMUNE was associated with improved progression-free sur-
vival (PFS) and OS, thus proposing EPIMMUNE as a good predictor of immunotherapy response
[27]. A second independent study described a global DNA-methylation signature in TGCA tissue
samples of lung cancer and melanoma that correlated loss of DNA methylation with tumoral CD8+
T cell infiltration, revealing poor prognosis associated with weaker tumor immunity that was indepen-
dent of mutation burden [67]. Moreover, disruption of the ten-eleven translocation methylcytosine
dioxygenase 2 (TET2) gene in a single clone of CAR-T cells was associated with enhanced cytotoxic
activity of a CAR-T against CD19 antigen (CART19) upon ex vivo restimulation. Infusion of CART19 in
a CLL patient showed clonal expansion of CART19 cells and a potent antitumoral response that led
to complete remission in that patient [68] (see Outstanding Questions). These observations emerged
from a completed nonrandomized pilot/Phase I study (single-arm) in patients with CD19+ leukemia
and lymphoma (NCT01029366ii). Patient outcome correlated with vector integration site, including
proximity to epigenetic chromosomal features such as the repressive mark H4R3me2 and the chro-
matin hyperacetylation-associated geneBRD3 [69]. In another example, transcriptomic data revealed
that the extent of alternative promoter usage at 2732 sites in gastric cancer biopsies correlated with
immune evasion and resistance to anti-PD-1 Ab immune checkpoint inhibition in gastric cancer pa-
tients [70], suggesting that alternative promoter usage might have potential as a predictive biomarker
for immunotherapy.
In conclusion, the leverage of epigenetic changes controlling tumor-associated immune responses
to reinforce immunotherapy may be a promising route for therapeutic intervention in cancer patients
and certainly deserves further robust investigation because many unknowns remain, particularly
when attempting to predict responses across different tumor types. In particular, given the need
to associate reliable biomarkers with immunotherapy success, epigenetic changes that might
accompany and/or be predictive of treatment outcomes are desirable, and may be relevant to the
development of precise diagnostic and stratification strategies (Figure 2).
Epigenetic Drugs To Boost Immunotherapy-Based Strategies
The highly dynamic nature of epigenetic regulation has been harnessed from a therapeutic point of
view through the development of drugs (epidrugs) that target the chromatin-modifying machinery
and affect epigenetic changes (Box 3). The reversibility of epigenetic modifications has enabled
pharmacological interventions with DNA hypomethylating agents (HMAs) and histone deacetylase
inhibitors (HDACis).
Clinical and Preclinical Trials Combining Epidrugs and Immunotherapy
A challenging aspect of cancer management is the development of resistance to treatment, and
this is a major limitation of many anticancer therapeutic approaches. The immunomodulatory
effect of epigenetic drugs can be leveraged to enhance the antitumor effect of immunotherapy,
as shown in transplantable murine models of mammary carcinoma and mesothelioma where
combining the DNA HMA 5-aza-2′-deoxycytidine (5-AZA-CdR) with an anti-CTLA-4 monoclonal
Ab led to increased antitumor activity relative to controls [71]. This study set the rationale for a single-
arm Phase Ib trial using the DNA HMA guadecitabine combined with ipilimumab (anti-CTL4 Ab) in
patients with unresectable stage III/IV melanoma (NCT02608437iii). Treatment safety and
tolerance were assessed in the trial, together with treatment-related immunomodulatory effects
including activation of immune-related pathways, upregulation of HLA-I by melanoma cells, and in-
creased numbers of CD8+PD-1+ T cells and CD20+ B cells at the tumor site post-treatmentTrends in Immunology, August 2020, Vol. 41, No. 8 685
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Figure 2. Epigenetic Mechanisms in the Tumor Microenvironment (TME) That Are Relevant to Cancer
Immunotherapy. DNA and histone methylation can shape the TME by regulating immune-related gene expression. DNA
and histone methylation by DNMT1 and EZH2, respectively, result in downregulation of the chemoattractant cytokine
genes Cxcl9 and Cxcl10, thereby dampening CD8+ T cell recruitment to mouse ovarian tumors [35]. Interferon (IFN)-γ-
induced Cxcl9 secretion by antigen-presenting cells (APCs) is impaired because of decreased CD8+ T cell infiltration upon
Ccl5 methylation in tumor cells [53]. Leukemia inhibitory factor (LIF)-mediated EZH2 recruitment to the Cxcl9 promoter
triggers its epigenetic silencing in tumor-associated macrophages (TAMs) [52]. Immunological synapse formation and
antigen presentation, which are necessary for an effective antitumor cytotoxic response, may be epigenetically silenced in
tumor cells by methylation [58]. Finally, methylation of genes in programmed cell death 1 (PD-1)+CD8+ T cells can induce
an ‘exhausted’ state that is refractory to effector response rescue with anti-PD-1 antibody therapies [43]. Red crosses
represent transcriptional repression. This figure was created using BioRender (https://biorender.com/). Abbreviations: CK,
cytokine; DC, dendritic cell; DNMT, DNA methyltransferase; Th1, type 1 T helper cell.
Trends in Immunologyrelative to baseline [72]. Treatment with hypomethylating drugs has also been shown to cause
upregulation of CD274, PDCD1LG2, and CTLA4 in myelodysplastic syndrome (MDS) and
AML CD34+ cells; patients resistant to treatment with the demethylating agent decitabine
showed higher expression of such genes relative to sensitive patients [73]. In addition,
PDCD1 promoter demethylation in CD4+ and CD8+ T cells from MDS or AML patients after
5-AZA treatment tended to show a poorer response to treatment and shorter overall response
(OR) than patients with a methylated PDCD1 promoter [74]. This has established a rationale for686 Trends in Immunology, August 2020, Vol. 41, No. 8
Outstanding Questions
Are we putting the ‘CART’ before the
horse? Is it necessary to further
characterize the human epigenome
before immunotherapy administration
because treatment itself may cause
epigenetic alterations in tumor cells,
and because most immunotherapy
treatments are administered as
second-line therapy? Could this new
knowledge contribute to new combi-
natorial strategies to overcome immu-
notherapy resistance?
Is it worth studying DNA methylation
changes in patient-derived CD8+ T
lymphocytes induced by immunother-
apy as a means of monitoring bio-
markers of immunotherapy response?
Should efforts be devoted to identifying
unique universal biomarkers for each
type of cancer, or should they instead
be devoted to defining 'response
signatures' for patient stratification?
How much do epigenetic tests reflect
tumor heterogeneity? Does it make
more sense to aim for single-cell reso-
lution? The TME is important in treat-
ment resistance, but cell clonality
could be the key to understanding
specific epigenetic changes that drive
treatment failure or success. Could
this provide a rationale for target inser-
tion strategies in the design of CAR-T
cell therapies?
Will technology allow the use of
epigenetic biomarkers in routine
clinical settings to predict or monitor
immunotherapy response? It is still
necessary to simplify the methods
and decrease the costs of measuring
epigenetic biomarkers.
Is the medical community prepared
to adopt the use of epigenetic
biomarkers as a means to develop
precision medicine? How can the use
of epigenetic biomarkers be exploited
so that these are translated from the
bench to the bedside?
Box 3. Epidrugs Currently Accepted for Clinical Use
DNMT Inhibitors
Hypomethylating agents (HMAs) currently approved for clinical use are the nucleotide analogs 5-aza-2-deoxycytidine (5-
AZA) and decitabine (5-AZA-2′-deoxycytidine, 5-AZA-CdR). These molecules are incorporated into the DNA of dividing
cells, causing irreversible binding and degradation of DNMTs, and subsequent activation of DNA damage response
(DDR) pathways [91]. The activation of the DDR triggers apoptosis of highly proliferative cells, promoting cytotoxicity in
addition to the epigenetic effect of HMAs.
HDAC Inhibitors
Vorinostat (suberoylanilidehydroxamic acid, SAHA) inhibits the enzymatic activity of class I and II HDACs [92]. It was first
approved by the FDA in 2006 for the treatment of progressive, persistent, or recurrent (relapsed/refractory) cutaneous
T cell lymphoma (CTCL) [93]. Romidepsin (cyclic peptide and depsipeptide) blocks HDAC activity, causing apoptosis. It
was approved by the FDA for CTCL in 2007 and for peripheral T cell lymphoma (PTCL) in 2011. The hydroxamate-type
class I, II, and IV HDAC inhibitor belinostat was approved for relapsed or refractory PTCL in 2014. Finally, in 2015, the
FDA approved panobinostat, a nonselective pan-HDAC inhibitor (in combination with bortezomib and dexamethasone)
for the treatment of multiple myeloma (MM).
Emerging Epigenetic-Based Therapies
Drug discovery devoted to the search for novel compounds that specifically target or reverse cancer-promoting epigenetic
modifications is a fast-expanding field. Upon screening with a library of several epigenetic targeting compounds, an aurora
kinase inhibitor has been shown to kill thyroid cancer cell lines efficiently, making it a potentially strong candidate for novel
epigenetic treatment of this cancer type [94]. A newly developed mutant IDH1 inhibitor (DS-1001b) has shown promising
antitumor properties in chondrosarcoma cell lines [95]. Ricolinostat, the first selective HDAC6 inhibitor [96], is currently
being tested in a Phase Ib/Phase II clinical trial to treat MM in combination with pomalidomide and dexamethasone. This
ongoing open-label trial recruited a total of 101 patients, with one study arm to assess safety and best dose (Phase Ib) as
well as overall response to treatment (Phase II) in relapsed and refractoryMM (NCT01997840xiii) Other small molecules that
selectively inhibit HDAC6 are showing greater efficacy and promising results in preclinical settings [97,98]. Novel experi-
mental approaches to promote targeted epigenome editing, such as directed integration of CpG-free DNA to induce de
novoDNAmethylation and to allow the correction of abnormal epigenetic modifications on disease-causing loci, may have
therapeutic potential and warrant further investigation [99].
Trends in Immunologyevaluating the success of combinatorial therapy with HMAs and ICB in AML and MDS patients
[75,76]. Moreover, treatment with CDK4/6 inhibitors reduced DNMT1 mRNA and protein
expression, causing hypomethylation of immune-related genes (such as those encoding
STATs and IRFs), in mouse tumor models (MMTV-rtTA/tetO-HER2, MMTV-PyMT) and pa-
tients with breast and colon carcinoma, enhancing antitumor immunity by both promoting
antigen presentation and reducing Treg cell expansion relative to controls [77]. The combina-
tion of CDK4/6 inhibitors with anti-PD-L1 Ab therapy in these mouse models led to tumor re-
gression and resistance to rechallenge with tumoral cells compared with untreated mice [77].
In line with this, a novel dual inhibitor that targets both G9a and DNMT has been used in combi-
nation with anti-PD-L1 Ab therapy in a mouse transgenic model of bladder cancer (PtenloxP/loxP;
Trp53loxP/loxP; Rb1loxP/loxP; Rbl1−/−), and enhanced the antitumor response by increasing CD8+ T
cell and NK cell tumor infiltration and inducing tumor regression relative to both untreated mice
and anti-PD-L1-Ab-only treatedmice [78]. In the case of HDAC inhibitors, entinostat is a synthetic
benzamide that selectively inhibits class I and IV HDACs and is being investigated in clinical trials in
combination with anti-PD-1 Ab therapy (pembrolizumab) for colorectal cancer and ICB-resistant
melanoma [79–81] and NSCLC [82–84]. Figure 3 summarizes selected ongoing clinical trials.
Concluding Remarks
Immunotherapy treatments have led to a major breakthrough on the road to monitoring, control-
ling, and eliminating particular malignancies. However, because every cancer is unique, efforts
must be concentrated on disentangling the way in which each tumor type manifests at the
molecular level and, consequently, how treatments can affect the development and potentialTrends in Immunology, August 2020, Vol. 41, No. 8 687
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Figure 3. Timeline of the Combinatorial Use of Epigenetic Drugs with Immunotherapy in Clinical Trials. Examples of ongoing clinical trials using different
combinations tested for solid tumor and hematological malignancies are shown. Drug names of DNA methyltransferase inhibitors (DNMTis) and histone deacetylase
inhibitors (HDACis), as well as immune checkpoint inhibitor molecules, are shown. Cancer types treated in the trial are illustrated with respect to the affected organ. The
state of the trial (recruiting, active, or completed) is indicated. Overall response (OR), progression-free survival (PFS), partial response (PR), and stable disease (SD) are
shown for each clinical trial according to published data (NCT02890329iv, NCT02638090v, NCT02437136vi, NCT02508870vii, NCT02397720viii, NCT02845297ix,
NCT03765229x, NCT02775903xi, NCT02260440xii) [75,76,79–81,83]. Abbreviations: AML, acute myeloid leukemia; 5-AZA, 5-aza-2-deoxycytidine; CRC, colorectal
cancer; CTLA-4, cytotoxic T-lymphocyte antigen 4; MDS, myelodysplastic syndrome; NSCLC, non-small cell lung cancer, PD-1, programmed cell death 1.
Trends in Immunologyeradication of each individual tumor. This knowledge must be translated into updated medical
guidelines if specific and effective therapies for different cancer types are to be deployed. One
way to implement personalized medicine for cancer relies, in part, on identifying robust bio-
markers that might not only predict response to immunotherapy but also factor in individual
differences and dynamic changes caused by the disease course itself and/or by the treatment.
In this respect, epigenetic biomarkers, including epigenetic signatures, might represent sensitive
predictors of the predisposition of each patient for response to treatment. As such, they might
offer valuable mechanistic information to potentially prevent or interfere with a desired therapeutic
response. Nonetheless, epigenetic and novel immunotherapy treatments are both nascent tools
in clinical practice, and further research will be necessary to discover and develop reliable epige-
netic biomarkers. By leveraging this knowledge, new-generation epigenetic drugs suitable for
combining with immunotherapy might be designed (see Outstanding Questions). We emphasize
that the availability of effective epigenetic biomarkers and new combinatorial approaches are likely
to increase the chances of success in cancer therapeutics.
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